# Justification for the selection of a candidate CoRAP substance

4,4'-Methylenediphenyl diisocyanate, oligomeric

reaction products with

**Substance Name (Public Name):** butane- 1,3-diol, 2,4'-

diisocyanato-

diphenylmethane, 2,2'oxydiethanol and propane-1,2-diol

**Chemical Group:** 

**EC Number:** 500-415-1

**CAS Number:** 158885-29-1

**Submitted by:** Health Board, Estonia

**Published:** 20/03/2013

#### **NOTE**

This document has been prepared by the evaluating Member State given in the CoRAP update.

# **Contents**

1		NTITY OF THE SUBSTANCE Name and other identifiers of the substance	3
2	2.1	SSIFICATION AND LABELLING Harmonised Classification in Annex VI of the CLP Proposal for Harmonised Classification in Annex VI of the CLP Self classification	4 4 4
3	3.1 3.2 3.3	TIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE Legal basis for the proposal Grounds for concern Information on aggregated tonnage and uses Other completed/ongoing regulatory processes that may affect suitability for substance evaluation	5 5 5
	3.5	Information to be requested to clarify the suspected risk	6
	3.6	Potential follow-up and link to risk management	6

### 1 IDENTITY OF THE SUBSTANCE

# 1.1 Name and other identifiers of the substance

**Table 1: Substance identity** 

Public Name:	4,4'-Methylenediphenyl diisocyanate, oligomeric reaction products with butane- 1,3-diol, 2,4'-diisocyanatodiphenylmethane, 2,2'-oxydiethanol and propane-1,2-diol
EC number:	500-415-1
EC name:	4,4'-Methylenediphenyl diisocyanate, oligomeric reaction products with butane- 1,3-diol, 2,4'-diisocyanatodiphenylmethane, 2,2'-oxydiethanol and propane-1,2-diol
CAS number (in the EC inventory):	158885-29-1
CAS number:	
CAS name:	1,3-Butanediol, polymer with 1-isocyanato-2-[(4-isocyanatophenyl)methyl]benzene, 1,1'-methylenebis[4-isocyanatobenzene], 2,2'-oxybis[ethanol] and 1,2-propanediol
IUPAC name:	
Index number in Annex VI of the CLP Regulation	
Molecular formula:	C14 H10 NO (C15 H12 N2 O2 R)n NCO where R = C4 H8 O2 (1,3-BD unit) or C4 H8 O3 (DEG unit) or C3 H6 O2 (MPG unit)
Molecular weight or molecular weight range:	ca. 315.0
Synonyms:	

**Type of substance**  $\square$  Mono-constituent  $\square$  Multi-constituent  $\boxtimes$  UVCB

### Structural formula:

#### 2 CLASSIFICATION AND LABELLING

#### 2.1 Harmonised Classification in Annex VI of the CLP

N/A

## 2.2 Proposal for Harmonised Classification in Annex VI of the CLP

N/A

#### 2.3 Self classification

The registration data includes the following self-classification:

#### According to CLP criteria:

- Acute Tox. 4; H332: Harmful if inhaled.
- Skin Irrit. 2; H315: Causes skin irritation, C ≥ 5%.
- Eye Irrit. 2; H319: Causes serious eye irritation, C ≥ 5%.
- Resp. Sens. 1; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- STOT Sing. Exp. 3. H335: May cause respiratory irritation, C ≥ 5%.
- STOT Rep. Exp. 2. H373: May cause damage to organs through prolonged or repeated exposure.
- Skin Sens. 1; H317: May cause an allergic skin reaction.
- Carc. 2; H351: Suspected of causing cancer.
- EUH204: Contains isocyanates. May produce an allergic reaction.

#### According to DSD criteria:

- Xn; R20 Harmful; Harmful by inhalation.
- Xn; R48/20 Harmful; Harmful: danger of serious damage to health by prolonged exposure through inhalation.
- Xi; R36/37/38 Irritant; Irritating to eyes, respiratory system and skin.
- R42/43 May cause sensitisation by inhalation and skin contact.
- Carc. Cat. 3; R40 Limited evidence of a carcinogenic effect.

# 3 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

	_	_	_	_
<b>3</b> 1	l enal	hacic	for the	proposal

oxtimes Article 44(1) (refined prioritisation criteria for substance evaluation)						
☐ Article 45(5) (Member State priority)						
2.2 Crounds for s	00000	_				
3.2 Grounds for c	onceri					
☐ (Suspected) CMR ☐ Wide dispersive use ☐ Cumulative ex					☐ Cumulative exposure	
☐ (Suspected) Sensitiser		☐ Consumer use			☐ High RCR	
☐ (Suspected) PBT		☐ Exposure of sensitive populations		ns	□ Aggregated tonnage	
☐ Suspected endocrine dis	sruptor	☐ Other (provide	e further details be	elow)		
It is unclear if hydrolysis of the substance is complete or not. There is also no information on degradation of hydrolysis products. The substance appears to meet B and T criteria. According to Annex X (8.7.) of the REACH regulation, reproductive toxicity study should be done.						
3.3 Information on aggregated tonnage and uses  1 - 10 tpa						
⊠ 1000 – 10,000 tpa		☐ 10,000 - 100,000 tpa			·	
☐ 100,000 - 1000,000 tpa	a	☐ > 1000,000 tpa				
☐ Confidential						
Please provide further details						
☐ Industrial use	⊠ Profe	essional use	⊠ Consumer use		☐ Closed System	
Substance is used in several consumer products.						

EC no. 500-415-1 MSCA – Estonia Page 5 of 6

# 3.4 Other completed/ongoing regulatory processes that may affect suitability for substance evaluation

☐ Compliance check		☐ Dangerous substances Directive 67/548/EEC				
☐ Testing proposal		☐ Existing Substances Regulation 793/93/EEC				
☐ Annex VI (CLP)		☐ Plant Protection Products Regulation 91/414/EEC				
☐ Annex XV (SVHC)		☐ Biocidal Products Directive 98/8/EEC				
☐ Annex XIV (Authoris	sation)		☐ Other (provide further details below)			
Annex XVII (Restriction)						
Please provide further	details					
3.5 Information	n to be requeste	d to	clarify the s	uspected risk		
☐ Information on toxicological properties			☐ Information on physico-chemical properties			
☐ Information on fate			☐ Information on physical chemical properties  ☐ Information on exposure			
	oxicological properties		☐ Information on uses			
			Illioilliation on uses			
Other (provide furth	<del>-</del>					
Requested information should help to understand how much of the substance reach to the environment, behavior in the environment, completeness of the hydrolysis, degradation of the hydrolysis products.						
	requirements for repro	oductiv	ve toxicity endpo	oint.		
			, .			
3 6 Potential fo	allow-up and link	, to r	ick manage	ment		
3.6 Potential follow-up and link to risk management						
☐ Restriction	☑ Harmonised C&L	⊠ Αι	uthorisation	$\square$ Other (provide further details)		
Please provide further details						

EC no. 500-415-1 MSCA – Estonia Page 6 of 6